Conundrums in CINV Prevention and Management - priME Oncology
Webcast
Webcast

Conundrums in CINV Prevention and Management

Facing Clinical Challenges to Improve Patient Outcomes

Not a member of My prIME? Join now for instant access.

Dr Eric Roeland summarizes expert discussion from a symposium held at the MASCC 2019 annual meeting in San Francisco, providing answers to the toughest questions surrounding treatment of chemotherapy-induced nausea and vomiting. The full symposium audio and slides are also provided, featuring expert commentary and case-based panel discussions.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Aug 8, 2019

Expiration Date

Aug 8, 2020

  • Picking the right strategy: guidelines vs personalized management
  • Tackling clinical conundrums in CINV: panel case discussions

Chair

  • Eric J. Roeland, MDMassachusetts General Hospital
    Boston, Massachusetts, United States

This educational activity is designed to meet the needs of oncologists, hematologists, nurses, and other healthcare professionals involved in the treatment of patients with CINV.

After successful completion of this educational activity, participants should be able to:

  • Evaluate current antiemetic therapies for the prevention and management of chemotherapy-induced nausea and vomiting (CINV)
  • Select optimal antiemetic therapy based on current guidelines and treatment- and patient-related risk factors
  • Identify best practices for management of challenging issues such as delayed CINV, anticipatory nausea and vomiting, and breakthrough CINV

This educational activity is supported by a grant from Helsinn.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.   Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.75 hour(s)

To contact Postgraduate Institute for Medicine, please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Aapro has disclosed that he has received consulting fees and fees for non-CME/CE services received directly from a commercial interest or their agents from G1 Therapeutics, Helsinn, Lilly, Mundipharma, Novartis, Pfizer, and Taiho. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Clark-Snow has disclosed that she has received consulting fees from Helsinn and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fernandez-Ortega has disclosed that she has received consulting fees from VIFOR Consulting. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Roeland has disclosed that he has received consulting fees from American Imagining Management, Asahi, BASF, Immuneering, and NAPO Pharmaceuticals. He also disclosed participation in advisory boards for Heron and Vector Oncology. He also disclosed participation on data safety monitoring boards for Cellceutix, Galera Therapeutics, and Orgenics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed no relevant relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.